Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | -4.17% | -11.54% | -25.81% |
Mar. 25 | Transcript : Prescient Therapeutics Limited - Special Call | |
Feb. 23 | Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 1.89M 1.25M | Sales 2023 | 2.43M 1.6M | Capitalization | 65.23M 43.1M |
---|---|---|---|---|---|
Net income 2022 | -5M -3.3M | Net income 2023 | -7M -4.63M | EV / Sales 2022 | 47.2 x |
Net cash position 2022 | 12.28M 8.12M | Net cash position 2023 | 21.92M 14.48M | EV / Sales 2023 | 17.8 x |
P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-8.41
x | Employees | 3 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.49% |
Latest transcript on Prescient Therapeutics Limited
1 day | -4.17% | ||
1 week | -11.54% | ||
Current month | -11.54% | ||
1 month | -14.81% | ||
3 months | -19.30% | ||
6 months | -20.69% | ||
Current year | -25.81% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 14-11-27 | |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Engle
CHM | Chairman | 69 | 14-11-27 |
James Campbell
BRD | Director/Board Member | - | 14-11-27 |
Ellen Feigal
BRD | Director/Board Member | 69 | 23-05-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 0.046 | -4.17% | 2,033,288 |
24-05-02 | 0.048 | -4.00% | 553,602 |
24-05-01 | 0.05 | -3.85% | 440,054 |
24-04-30 | 0.052 | 0.00% | 858,616 |
24-04-29 | 0.052 | 0.00% | 762,848 |
Delayed Quote Australian S.E., May 03, 2024 at 01:36 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-25.81% | 25.29M | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |
- Stock Market
- Equities
- PTX Stock